Linical Co., Ltd.

TSE:2183 Voorraadrapport

Marktkapitalisatie: JP¥8.2b

Linical Toekomstige groei

Future criteriumcontroles 3/6

Linical is forecast to grow earnings and revenue by 23.8% and 2% per annum respectively. EPS is expected to grow by 23.9% per annum. Return on equity is forecast to be 6.5% in 3 years.

Belangrijke informatie

23.8%

Groei van de winst

23.9%

Groei van de winst per aandeel

Life Sciences winstgroei28.4%
Inkomstengroei2.0%
Toekomstig rendement op eigen vermogen6.5%
Dekking van analisten

Low

Laatst bijgewerkt17 May 2024

Recente toekomstige groei-updates

Recent updates

There May Be Some Bright Spots In Linical's (TSE:2183) Earnings

May 22
There May Be Some Bright Spots In Linical's (TSE:2183) Earnings

Some Linical Co., Ltd. (TSE:2183) Shareholders Look For Exit As Shares Take 26% Pounding

Mar 08
Some Linical Co., Ltd. (TSE:2183) Shareholders Look For Exit As Shares Take 26% Pounding

Linical (TSE:2183) Is Paying Out A Larger Dividend Than Last Year

Feb 26
Linical (TSE:2183) Is Paying Out A Larger Dividend Than Last Year

Winst- en omzetgroeiprognoses

TSE:2183 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (JPY Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
3/31/202713,000670722N/A1
3/31/202612,400530920N/A1
3/31/202512,600600812N/A1
6/30/202412,151253N/AN/AN/A
3/31/202412,3073381,0331,065N/A
12/31/202312,518680N/AN/AN/A
9/30/202312,6607141,8051,811N/A
6/30/202312,730931N/AN/AN/A
3/31/202312,5161,0041,8261,839N/A
12/31/202212,188843N/AN/AN/A
9/30/202211,9531,0061,4121,454N/A
6/30/202211,639799N/AN/AN/A
3/31/202211,5557901,5851,631N/A
12/31/202111,360906N/AN/AN/A
9/30/202110,8208041,2891,343N/A
6/30/202110,639805N/AN/AN/A
3/31/202110,279539-4523N/A
12/31/202010,262241N/AN/AN/A
9/30/202010,52723961127N/A
6/30/202010,679268N/AN/AN/A
3/31/202010,9354821,0611,192N/A
12/31/201910,944508N/AN/AN/A
9/30/201911,090409104201N/A
6/30/201911,234541N/AN/AN/A
3/31/201911,313568-852-796N/A
12/31/201810,975853N/AN/AN/A
9/30/201810,4061,147446515N/A
6/30/20189,7361,177N/AN/AN/A
3/31/20189,1131,295N/A1,360N/A
12/31/20178,8701,281N/AN/AN/A
9/30/20178,6451,237N/A2,133N/A
6/30/20178,5411,381N/AN/AN/A
3/31/20178,3551,447N/A2,291N/A
12/31/20168,1311,375N/AN/AN/A
9/30/20167,9161,331N/A1,173N/A
6/30/20167,8911,368N/AN/AN/A
3/31/20167,6661,330N/A1,817N/A
12/31/20157,4201,154N/AN/AN/A
9/30/20156,6441,015N/A1,775N/A
6/30/20155,549579N/AN/AN/A
3/31/20154,872437N/A690N/A
12/31/20144,231465N/A597N/A
9/30/20144,022429N/A437N/A
6/30/20143,909445N/A480N/A
3/31/20143,721449N/A249N/A
12/31/20133,692473N/A195N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: 2183's forecast earnings growth (23.8% per year) is above the savings rate (0.3%).

Winst versus markt: 2183's earnings (23.8% per year) are forecast to grow faster than the JP market (8.9% per year).

Hoge groeiwinsten: 2183's earnings are expected to grow significantly over the next 3 years.

Omzet versus markt: 2183's revenue (2% per year) is forecast to grow slower than the JP market (4.2% per year).

Hoge groei-inkomsten: 2183's revenue (2% per year) is forecast to grow slower than 20% per year.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: 2183's Return on Equity is forecast to be low in 3 years time (6.5%).

Ontdek groeibedrijven

7D

1Y

7D

1Y

7D

1Y